eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
2/2018
vol. 22
 
Share:
Share:
more
 
 
abstract:
Original paper

Rebound thymic hyperplasia after bone marrow transplantation in children with haemato-oncological diseases

Taner Arpaci, Barbaros Sahin Karagun

Contemp Oncol (Pozn) 2018; 22 (2): 95-98
Online publish date: 2018/04/23
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Aim of the study
To evaluate prevalence of rebound thymic hyperplasia (RTH) after bone marrow transplantation (BMT) in paediatric patients with haemato-oncological diseases.

Material and methods
Between February 2013 and December 2017, BMT was performed in 189 paediatric patients with haemato-oncological diseases in our institution. Fifty-six patients who underwent at least two chest computed tomography (CT) exams performed before and after BMT were included in the study. Maximum transverse and anterior-posterior (AP) diameters and CT attenuation of the thymus were measured on axial images. Thymic enlargement was considered when both transverse and AP diameters increased. RTH was defined as the presence of thymic enlargement on CT after BMT relative to the CT taken before.

Results
Twenty of 56 patients (36%) demonstrated RTH (12 boys, 8 girls; age range = 4-18 years; median age = 9.8 years). In 20 patients with RTH, seven patients (35%) were diagnosed with ALL, five patients (25%) with thalassemia, two patients (10%) with AML, and one patient (5%) with various diseases. Mean follow-up period between pre-BMT CT and BMT was 46 days, which was 239 days between BMT and post-BMT CT. Mean thymic transverse and AP diameters were 9 mm and 16 mm, respectively, before BMT, which were 17 mm and 33 mm after BMT. Mean HU was 57 on contrast enhanced and 35 on unenhanced images before BMT, which were 59 and 36, respectively, after BMT.

Conclusions
RTH is common finding after BMT in children with various haemato-oncological diseases and should be taken under consideration in paediatric patients after BMT.

keywords:

thymus, rebound hyperplasia, haemato-oncological disease, computed tomography

references:
Küpeli S. Rebound thymic hyperplasia. Cukurova Med J 2017; 42: 799-800.
Araki T, Sholl LM, Gerbaudo VH, Hatabu H. Thymic measurements in pathologically proven normal thymus and thymic hyperplasia: Intra and interobserver variability. Acad Radiol 2014; 21: 733-742.
Ackman JB, Kovacina B, Carter BW, Wu CC, Sharma A, Shepard J-AO, Halpern EF. Sex difference in normal thymic appearance in adults 20-30 years of age. Radiology 2013; 268: 245-253.
Nishino M, Ashiku SK, Kocher ON, Thurer RL, Boiselle PM, Hatabu H. The thymus: a comprehensive review. RadioGraphics 2006; 26: 335-348.
Araki T, Sholl LM, Gerbaudo VH, Hatabu H, Nishino M. Imaging characteristics of pathologically proven thymic hyperplasia: identifying features that can differentiate true from lymphoid hyperplasia. AJR Am J Roentgenol 2014; 202: 471-478.
Sfikakis PP, Gourgoulis GM, Moulopoulos LA, Kouvatseas G, Theofilopoulos AN, Dimopoulos MA. Age-related thymic activity in adults following chemotherapy-induced lymphopenia. Eur J Clin Invest 2005; 35: 380-387.
Chen CH, Hsiao CC, Chen YC, Ko SF, Huang SH, Huang SC, Hsieh KS, Sheen JM. Rebound Thymic Hyperplasia after Chemotherapy in Children with Lymphoma. Pediatr Neonatol 2017; 58: 151-157.
Bangerter M, Behnisch W, Griesshammer M. Mediastinal masses diagnosed as thymus hyperplasia by fine needle aspiration cytology. Acta Cytol 2000; 44: 743-777.
Yarom N, Zissin R, Apter S, Hertz M, Rahimi-Levene N, Gayer G. Rebound thymic enlargement on CT in adults. Int J Clin Pract 2007; 61: 562-588.
Kissin CM, Husband JE, Nicholas D, Eversman W. Benign thymic enlargement in adults after chemotherapy: CT demonstration. Radiology 1987; 163: 67-70.
Wittram C, Fischman AJ, Mark E, Ko J, Shepard JA. Thymic enlargement and FDG uptake in three patients: CT and FDG positron emission tomography correlated with pathology. AJR Am J Roentgenol 2003; 180: 519-522.
Nakahara T, Fujii H, Ide M, Nishiumi N, Takahashi W, Yasuda S, Shothsu A, Kubo A. FDG uptake in the morphologically normal thymus: comparison of FDG positron emission tomography and CT. Br J Radiol 2001; 74: 821-824.
Brink I, Reinhardt MJ, Hoegerle S, Altehoefer C, Moser E, Nitzsche EU. Increased metabolic activity in the thymus gland studied with 18F-FDG PET: age dependency and frequency after chemotherapy. J Nucl Med 2001; 42: 591-595.
Ackman JB, Wu CC. MRI of the thymus. AJR Am J Roentgenol 2011; 197: 15-20.
Inaoka T, Takahashi K, Mineta M, et al. Thymic hyperplasia and thymus gland tumors: differentiation with chemical shift MR imaging. Radiology 2007; 243: 869-876.
Priola AM, Priola SM, Ciccone G, et al. Differentiation of rebound and lymphoid thymic hyperplasia from anterior mediastinal tumors with dual-echo chemical-shift MR imaging in adulthood: reliability of the chemical-shift ratio and signal intensity index. Radiology 2015; 274: 238-249.
Priola AM, Gned D, Marci V, Veltri A, Priola SM. Diffusion-weighted MRI in a case of nonsuppressing rebound thymic hyperplasia on chemical-shift MRI. Jpn J Radiol 2015; 33: 158-163.
Bakan S, Kandemirli SG, Dikici AS, et al. Evaluation of anterior mediastinal solid tumors by CT perfusion: a preliminary study. Diagn Interv Radiol 2017; 23: 10-14.
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe